Selective dopamine and norepinephrine reuptake inhibitor

Plain-language summaryIntrigue 68 / 100

Solriamfetol, sold as Sunosi, is a wakefulness-promoting medication FDA-approved in 2019 for daytime sleepiness in narcolepsy and obstructive sleep apnea. It is a selective dopamine and norepinephrine reuptake inhibitor with clean pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

60/100

First approved DNRI for EDS with a credible TAAR1 angle that separates it mechanistically from legacy stimulants

Look, solriamfetol is a legitimate compound with a real clinical story behind it. Approved in 2019 for excessive daytime sleepiness in narcolepsy and OSA, it arrived with a full TONES Phase 3 program: five trials, meaningful MWT improvements (roughly 10 to 12 minutes versus 2.1 minutes for placebo at 150 to 300 mg in narcolepsy), and 52 weeks of open-label extension data. For a wake-promoting agent, thats a more rigorous evidence base than most things in this library carry. The TONES 5 withdrawal phase is particularly well-designed; participants switched to placebo showed ESS worsening of 5.3 points versus 1.6 points for those who stayed on drug, which is clean confirmation the pharmacology is doing real work rather than a placebo-and-habituation story.

The mechanism is where things get interesting. Primary classification is DNRI: DAT inhibition at roughly 2.9 micromolar IC50, NET at 4.4 micromolar, minimal SERT activity. What we actually like about solriamfetol is the documented absence of monoamine-releasing activity. This isn’t a minor detail. The distinction between reuptake inhibition and monoamine release matters enormously when you’re trying to dissect dopamine pathway pharmacology without the downstream tachyphylaxis and sensitization you get with amphetamine-class releasing agents. Solriamfetol lets you hold that variable cleanly.

Then there’s the TAAR1 piece. The compound acts as a TAAR1 agonist with EC50 of roughly 10 to 16 micromolar, which overlaps its DAT and NET inhibitory potencies and sits within clinically relevant plasma concentration ranges. TAAR1 is an active research area right now: it’s implicated in dopamine system modulation, has psychiatry-relevant biology, and several programs are targeting it directly (ulotaront, ralmitaront). Solriamfetol isn’t a clean TAAR1 probe because the transporter activity dominates the pharmacological picture, but it’s a useful dual-mechanism tool if you’re asking how TAAR1 modulation intersects with catecholamine reuptake in a system where you can’t disentangle those two inputs with a single-target compound.

The PK profile is genuinely clean. About 95 percent oral bioavailability, less than 1 percent hepatic metabolism, essentially no CYP interaction liability, and predominant renal elimination as unchanged drug. The absence of active metabolites makes in vivo interpretation straightforward, and for researchers needing a well-characterized DNRI reference compound, the sourcing and analytical verification picture is cleaner than most peptides in this library.

What we dont love: solriamfetol is six years post-approval and the research frontier has largely moved elsewhere. The indication space, narcolepsy and OSA, is clinically important but not a hotbed of novel biology in 2025. The TAAR1 angle remains the most compelling research hook, but better-characterized TAAR1 probes exist for investigators specifically targeting that receptor system. This is a solid, well-evidenced compound with genuine utility for certain programs, particularly anyone studying wake-promotion pharmacology or needing a clean non-releasing catecholamine tool. It scores where it scores because it earned its evidence, but the frontier has moved on.

Novelty: 42
Mechanism promise: 62
In-category differentiation: 55
Evidence quality: 72
Translational signal: 78
Research bench value: 55

Rationale Strong Phase 3 evidence base across TONES 1-5 and a clean translational story hold the score up; novelty is constrained because this is a six-year-old approved drug in a non-frontier indication, and while the TAAR1 contribution is real it doesn’t make solriamfetol a primary probe for that receptor. Schedule IV cap at 75 doesn’t bind on the calculated score of 60.

Selective dopamine and norepinephrine reuptake inhibitor (DNRI) with trace amine-associated receptor 1 (TAAR1) agonist activity

A phenylalanine-derived dual dopamine-norepinephrine reuptake inhibitor developed by SK Biopharmaceuticals and commercialized by Jazz Pharmaceuticals as the first DNRI approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea.

Abstract

Solriamfetol (JZP-110, SKL-N05, ADX-N05) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) approved in the United States (March 2019) and the European Union (January 2020) for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA). Chemically derived from the amino acid D-phenylalanine, solriamfetol is the (R)-enantiomer of 2-amino-3-phenylpropyl carbamate and is supplied as the hydrochloride salt for oral administration. The compound inhibits the reuptake of dopamine (IC50 approximately 2.9 micromolar) and norepinephrine (IC50 approximately 4.4 micromolar) at their respective plasma membrane transporters (DAT and NET) with minimal activity at the serotonin transporter. In addition, solriamfetol acts as an agonist at the human trace amine-associated receptor 1 (TAAR1) with an EC50 of approximately 10 to 16 micromolar, a concentration range overlapping its DAT and NET inhibitory potencies and achieved at clinically relevant plasma levels. Critically, the compound does not promote monoamine release, distinguishing it mechanistically from amphetamine and its analogs and supporting its classification as a reuptake inhibitor rather than a releasing agent. The clinical development program comprised five pivotal trials (TONES 1 through TONES 5). The Phase 3 TONES 2 trial in 231 narcolepsy patients demonstrated that solriamfetol at 150 mg and 300 mg once daily produced statistically significant improvements in the Maintenance of Wakefulness Test (MWT) mean sleep latency (increases of 9.8 and 12.3 minutes, respectively, versus 2.1 minutes for placebo at 12 weeks) and in the Epworth Sleepiness Scale (ESS). The Phase 3 TONES 3 trial in 459 OSA patients demonstrated similar dose-dependent improvements at 37.5, 75, 150, and 300 mg doses. The long-term TONES 5 open-label extension in 643 participants confirmed maintenance of efficacy and tolerability over 52 weeks. A randomized withdrawal phase within TONES 5 demonstrated that participants switched to placebo experienced a return of sleepiness (ESS worsening of 5.3 points versus 1.6 points for those continuing solriamfetol), confirming sustained pharmacological activity rather than natural remission. Pharmacokinetics are notable for high oral bioavailability (approximately 95 percent), minimal hepatic metabolism (less than 1 percent of dose recovered as the sole inactive metabolite N-acetyl solriamfetol), and predominant renal elimination of unchanged drug through active tubular secretion. The elimination half-life is approximately 7.1 hours in subjects with normal renal function. Because metabolism is negligible, solriamfetol carries essentially no cytochrome P450 drug interaction liability. However, renal impairment substantially prolongs elimination (half-life increased approximately 1.2-, 1.9-, and 3.9-fold in mild, moderate, and severe renal impairment, respectively), requiring dose adjustment in moderate and severe renal impairment and avoidance in end-stage renal disease. The principal adverse events are headache, nausea, decreased appetite, insomnia, and anxiety. Solriamfetol produces small, dose-dependent increases in systolic blood pressure (0.5 to 2.5 mmHg), diastolic blood pressure, and heart rate (0.7 to 2.9 beats per minute), consistent with its noradrenergic mechanism. Concurrent use with monoamine oxidase inhibitors is contraindicated. The compound is designated Schedule IV in the United States, reflecting low but measurable abuse potential at supratherapeutic doses. This monograph reviews the chemistry, synthesis, and stereochemistry of solriamfetol; the dual-transporter and TAAR1 pharmacology; the comprehensive pharmacokinetic profile; the clinical evidence base across narcolepsy and OSA indications; the sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five wake-promoting agents against solriamfetol on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1441Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Selective dopamine and norepinephrine reuptake inhibitor

Solriamfetol

Abstract

Read the full monograph